In an era when startups often boast sprawling teams and years of research and development, Matthew Gallagher appears to have rewritten the script, with the assistance of AI.
From a $20,000 investment, the Los Angeles entrepreneur built Medvi, a telehealth company centered on weight-loss drugs and wellness products, into a business that generated more than $401 million in sales in its first year. In 2026, the company is projected to reach $1.8 billion.
The scale of that growth, if charted, would resemble a near-vertical ascent — less a steady climb than a sudden liftoff. Gallagher’s approach is equally unconventional. His operation is rooted in a growing trend known as “solopreneurship,” a one-person business model increasingly enabled by AI.
In Gallagher’s case, AI is not a tool so much as an infrastructure. By his account, it has been used to write code, manage bookkeeping and handle much of the day-to-day operations that would typically require entire departments. Aside from occasional help from his younger brother, the company has operated with minimal human staffing.
That efficiency helped Medvi capitalize on a surging market for GLP-1 drugs, including semaglutide and tirzepatide, medications widely used for weight loss. The company has since expanded into supplements targeting both men and women, broadening its reach in a lucrative and highly competitive sector.
The rise of businesses like Medvi has drawn attention from organizations such as the U.S. Chamber of Commerce, which has highlighted solopreneurship as an emerging force. On its website, the chamber points to a wide range of solo ventures, from pet sitting to consulting, though few approach the scale Gallagher has achieved.
But as Medvi’s profile has grown, so too has scrutiny. Questions have surfaced about the authenticity of some of the AI-generated content on the company’s website, including profiles of individuals described as medical professionals. Allegations that some of those figures may be fabricated or misleading have not been independently verified, but they have contributed to broader concerns about transparency in AI-driven businesses.
More concretely, federal regulators have taken notice.
In a Feb. 20 warning letter, the U.S. Food and Drug Administration said it had reviewed Medvi’s website and found that the company’s marketing of compounded semaglutide and tirzepatide products included “false or misleading claims.” The agency stated that representations suggesting Medvi was the compounder of those drugs were inaccurate and that certain promotional language could imply the products were FDA-approved when they were not.
“Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not,” the letter states.
Under federal law, the FDA said, such representations render the products “misbranded” and their distribution in interstate commerce a prohibited act.
The letter, issued by the agency’s Center for Drug Evaluation and Research, directed Medvi to take corrective action and warned that failure to do so could result in enforcement measures, including seizure or injunction.
The tension between rapid innovation and regulatory oversight is not new, but Medvi’s trajectory illustrates how quickly that gap can widen when technology accelerates every aspect of a business. AI has lowered barriers to entry, allowing entrepreneurs to build, market and scale companies at speeds once unimaginable. But it has also introduced new challenges, particularly around accuracy, accountability and the line between automation and misrepresentation.
For Gallagher, the same tools that enabled his company’s meteoric rise are now part of the conversation surrounding its future — whether Medvi ultimately becomes a case study in the power of AI-driven entrepreneurship or a cautionary tale about its limits.
